These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 34364728)
1. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. Li R; Jain RK; Sexton WJ Eur Urol; 2021 Oct; 80(4):e99. PubMed ID: 34364728 [No Abstract] [Full Text] [Related]
2. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940 [No Abstract] [Full Text] [Related]
3. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Vila-Reyes H; DeCastro GJ; McKiernan JM Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975 [No Abstract] [Full Text] [Related]
4. Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Bai Y; Yang Y; Tang Y Eur Urol; 2020 Jun; 77(6):e158. PubMed ID: 32199681 [No Abstract] [Full Text] [Related]
5. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43. Bandini M; Necchi A Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002 [No Abstract] [Full Text] [Related]
6. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Vila-Reyes H; Joel DeCastro G; McKiernan JM Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798 [No Abstract] [Full Text] [Related]
7. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. Panebianco V; Barentsz J; Narumi Y; Catto J; Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821 [No Abstract] [Full Text] [Related]
8. Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Yang Y; Wei X; Han P Eur Urol; 2019 Aug; 76(2):e33. PubMed ID: 31054785 [No Abstract] [Full Text] [Related]
9. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Li R; Spiess PE; Gilbert SM; Necchi A Eur Urol; 2019 Aug; 76(2):e34. PubMed ID: 31056228 [No Abstract] [Full Text] [Related]
10. Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15. Sundar S; Symonds P Eur Urol; 2021 Aug; 80(2):e49-e50. PubMed ID: 34024651 [No Abstract] [Full Text] [Related]
11. Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15. Hussain SA; Porta N; Hall E; Qureshi M; Lewis R; Huddart R; James ND Eur Urol; 2021 Aug; 80(2):e51-e52. PubMed ID: 34053780 [No Abstract] [Full Text] [Related]
12. Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9. Saad S; Osman NI; Chapple CR Eur Urol; 2022 Jan; 81(1):e16-e17. PubMed ID: 34740503 [No Abstract] [Full Text] [Related]
13. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100. Dev S Eur Urol; 2022 Jan; 81(1):e25. PubMed ID: 34663524 [No Abstract] [Full Text] [Related]
14. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306. Teoh JYC; Herrmann TRW; Babjuk M Eur Urol; 2019 Feb; 75(2):e27-e28. PubMed ID: 30262343 [No Abstract] [Full Text] [Related]
15. Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65. Linscott JA; Smith AB; Sammon JD Eur Urol; 2018 Apr; 73(4):e102-e103. PubMed ID: 29129400 [No Abstract] [Full Text] [Related]
16. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100: Reply from the European Association of Urology Equity, Diversity, and Inclusion Task Force. Carmen Mir M; Greenwell T; O'Kelly F; Proietti S; Laukhtina E; Mertens L; Morgenstern S; Ouzaid I; Eur Urol; 2022 Jan; 81(1):e26-e27. PubMed ID: 34772550 [No Abstract] [Full Text] [Related]
17. Re: Siobhan P. Lynch, Yu Shen, Ashish Kamat, et al. neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.020. Ismaili N Eur Urol; 2012 Sep; 62(3):e65-6. PubMed ID: 22682991 [No Abstract] [Full Text] [Related]
18. Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23. Herr HW Eur Urol; 2008 Jul; 54(1):23-4. PubMed ID: 18262335 [No Abstract] [Full Text] [Related]
19. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO). Necchi A; Messina A; Briganti A Eur Urol; 2018 Nov; 74(5):e107-e108. PubMed ID: 30318068 [No Abstract] [Full Text] [Related]
20. Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol 2020;77:733-41. Aning J; McCoubrie P; Oxley J Eur Urol; 2020 Nov; 78(5):e198-e199. PubMed ID: 32839000 [No Abstract] [Full Text] [Related] [Next] [New Search]